Marciniak, A.; Nawrocka-Rutkowska, J.; Brodowska, A.; Starczewski, A.; Szydłowska, I. Lymphangioleiomyomatosis with Tuberous Sclerosis Complex—A Case Study. J. Pers. Med.2023, 13, 1598.
Marciniak, A.; Nawrocka-Rutkowska, J.; Brodowska, A.; Starczewski, A.; Szydłowska, I. Lymphangioleiomyomatosis with Tuberous Sclerosis Complex—A Case Study. J. Pers. Med. 2023, 13, 1598.
Marciniak, A.; Nawrocka-Rutkowska, J.; Brodowska, A.; Starczewski, A.; Szydłowska, I. Lymphangioleiomyomatosis with Tuberous Sclerosis Complex—A Case Study. J. Pers. Med.2023, 13, 1598.
Marciniak, A.; Nawrocka-Rutkowska, J.; Brodowska, A.; Starczewski, A.; Szydłowska, I. Lymphangioleiomyomatosis with Tuberous Sclerosis Complex—A Case Study. J. Pers. Med. 2023, 13, 1598.
Abstract
Lymphangioleiomyomatosis (LAM) is characterized by lung cysts that cause lung deterioration, changes in the lymphatic system, and tumors in the kidneys. It mainly affects women of reproductive age and is a progressive disease. LAM can occur as an isolated disease or coexist with tuberous sclerosis (TSC). The source of LAM cells is unknown. Patients with confirmed LAM should be treated with an mTOR inhibitor, sirolimus, or everolimus. We present a case of LAM with TSC in a patient whose symptoms, including lymph nodes and chyaloperitoneum, mainly concern the abdominal cavity.
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.